In April 2026, Gyre initiated its adaptive Phase 2/3 clinical trial in oncology-related pulmonary complications, with the first patient enrolled. The trial is evaluating pirfenidone for ...

Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple ...

Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago.

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a ...

Detailed price information for Gyre Therapeutics Inc (GYRE-Q) from The Globe and Mail including charting and trades.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The MarketWatch News Department was not involved in the creation of this content. -- Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existing Phase 3 clinical ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Several systems from the hyperactive 2020 hurricane season, including many of the land-falling storms along the Gulf Coast, developed in a similar way, stemming from a breeding ground created by an ...